Board of Directors

Silvia Noiman, PhD, MBA: Executive Chairperson. Dr. Noiman is a leading entrepreneur and executive with over 20 years of experience in the Biopharmaceuticals Industry. She is a Venture Partner at Pontifax, founder of many of the Pontifax’s portfolio companies, including, cCAM Biotherapeutics Ltd. where she held an Executive Chairperson position and Eloxx Pharmaceuticals, where she has a CEO position. Previously she was Founder and Senior Vice President of Predix Pharmaceuticals bringing a small early stage drug discovery company from inception to about $500M publicly traded multi-product company progressing four discovery programs to late stage clinical trials and significant big pharma partnerships. Noiman has a PhD in Molecular Biology from Tel Aviv University and Post Doc from the Weizmann Institute of Science. Published numerous papers and co-inventor in several patents.

Mr. Mori Arkin, BA. Mr. Arkin owns and leads Arkin Holdings. He is a successful healthcare entrepreneur and was the principal shareholder and Chairman of Agis Industries Ltd. from its inception in 1983 until the merger with Perrigo (PRGO) in 2005. Over the last few years, Mr. Arkin used his knowledge, experience and financial capabilities to take an active part in companies within the pharmaceutical, medical device and biotech industry.

Prof Dan Peer, PhD: Founder and Inventor. Prof Peer is a principal investigator and Professor who leads an NIH-funded laboratory at Tel Aviv University, Israel.  Prof Peer completed his education in biochemistry and biophysics from Tel Aviv University, Israel (TAU). From 2005 to 2008, he worked at Harvard Medical School. He then joined the Department of Cell Research and Immunology, in the Faculty of life sciences at TAU to establish the laboratory of nanomedicine. Peer’s research was one of the first to demonstrate systemic delivery of RNAi using targeted nano-carriers to the immune system, and the first to utilize RNAi for in vivo validation of new drug targets within the immune system. Prof. Peer’s work was pioneering in the field of gut inflammation and he was involved in the development of antibodies that block lymphocytes homing into the gut during Inflammatory bowel disease. His work is published in premier scientific journals and he is the editor and author of several books in the field of nanomedicine. In addition, he is an associate editor of Journal of Controlled Release, and the editor (biology and medicine) in Nanotechnology. He is also a member of the editorial boards of numerous journals. Prof Peer has received more than 20 awards and honors, is a member of the Israel Young Academy of Science, and holds 45 pending and granted patents. He co-founded three companies based on his work aiming to bring the area of Nanomedicine into clinical practice.

Mr. Ran Nussbaum: Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, who has established three funds with over $220M under management and over 40 portfolio companies. Over the past ten years, Mr. Nussbaum has been managing the group’s activity alongside Mr. Tomer Kariv. He also served as CEO of Biomedix and Spearhead Ltd as well as Ocon Medical chairman of the board. Mr. Nussbaum’s real life experience in the life sciences arena, coupled with a 10-year experience in the business intelligence field, creates a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Mr. Nussbaum serves as a board member of many of the group’s portfolio companies, including Kite Pharma (public company) c-CAM, Insuline (public company), Eloxx, Bioblast (public company), TheraCoat, and Ocon Medical.

Mr. Ranan Grobman: Mr. Grobman has been an active investor in Israeli high-tech companies since 1999. He has served as a general partner of Jerusalem Global Ventures (JGV) since 2008 and has held different capacities of investment management and investment banking with Jerusalem Global since 1999. Today, Mr. Grobman is managing partner at Vaizra Investments Israel.

Dr. Pini Orbach, Ph.D: Dr. Orbach joined Arkin Holdings in February 2010 and serves as the head of Pharma at Arkin Holdings. He is a board member at HealOr Ltd. Prior to joining Arkin Holdings, Dr. Orbach served as CEO of several Health Care companies in Israel and abroad. He received his Ph.D., from the Department of Physiology and functional genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, MGH- Harvard Medical School.

Dr. Alon Lazarus, Ph.D: Biotech Investment Manager: Alon joined Arkin holdings in August 2013 as a Pharma and Life Science analyst. Prior to joining Arkin Holdings, Alon worked with the healthcare business development department of Yissum – The Research Development Company of the Hebrew University, as well as being an analyst for Integra Holdings. He holds a Ph.D. in molecular biology and an MBA from the Hebrew University of Jerusalem.